Epigenetics | New Technologies Transforming the Industrial Business
The global epigenetics market is projected to reach USD 1.60 billion by 2022 from USD 0.85 billion in 2016, at a CAGR of 13.3%
(firmenpresse) - According to a new market research report "Epigenetics Market by Product (Kit, Enzymes, Reagent, NGS, Mass Spectrometer, PCR, Bioinformatics), Application (Oncology, Cardiology, Immunology), Technology (DNA Methylation, Histone Modification), End User (Academic, CRO) - Global Forecast to 2022", published by MarketsandMarkets™, the market is projected to reach USD 1,605.7 million by 2022 from an estimated USD 854.0 million in 2017, at a CAGR of 13.5% during the forecast period.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=896
The major players in the Global Epigenetics Market are Illumina (US), Thermo Fisher (US), Diagenode (Belgium), QIAGEN (US), Merck Millipore (US), Abcam (UK), Active Motif (US), New England Biolabs (US), Agilent (US), Zymo Research (US), PerkinElmer (US), and Bio-Rad (US).
The key factors that are driving the growth of this market include the decreasing sequencing costs and time, increase in research activities to identify and develop inhibitors/drugs for various diseases, funding for epigenetics research, and rising prevalence of cancer.
Browse and in-depth TOC on "Epigenetics Market"
191 - Tables
37 - Figures
230 – Pages
North America accounted for the largest share of the Epigenetics Market in 2016, followed by Europe. Increase in epigenetics research activities, favorable government funding initiatives, high R&D expenditure, rising incidence of various diseases, and the presence of key players in the region are the key factors driving the growth of the Epigenetics Market in North America.
Major Market Developments
In July 2017, Agilent launched AriaDx Real-Time PCR System
In June 2017, Illumina launched Extended RAS Panel, a NGS kit
In January 2017, Illumina entered into an agreement with Koninklijke Philips (Netherlands) to integrate Ilumina’s sequencing systems with Philips’ IntelliSpace Genomics clinical informatics platform for oncology
Pharmaceutical companies and research laboratories require many such systems. Therefore, significant investments are required for procuring multiple, high-cost genomic instruments. End users such as academic research laboratories find it difficult to afford such systems as they have constricted budgets. High instrument costs, therefore, hinder their wide adoption, which is expected to restrict market growth during the forecast period.
List of Figures (37 Figures)
Figure 1 Research Design
Figure 2 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 3 Bottom-Up Approach
Figure 4 Top-Down Approach
Figure 5 Data Triangulation Methodology
Figure 6 Global Epigenetics Market, By Product, 2017 vs 2022 (USD Billion)
Figure 7 Global Epigenetics Market, By Application, 2017 vs 2022 (USD Billion)
Figure 8 Global Epigenetics Market, By Technology, 2017 vs 2022 (USD Billion)
Figure 9 Global Epigenetics Market, By End User, 2017 vs 2022 (USD Billion)
Figure 10 Geographic Snapshot: Epigenetics Market
Read more: https://www.prnewswire.com/news-releases/epigenetics-market-worth-16057-million-usd-by-2022-650610663.html
Weitere Infos zu dieser Pressemeldung:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales(at)marketsandmarkets.com
Datum: 13.09.2019 - 11:41 Uhr
Sprache: Deutsch
News-ID 1753156
Anzahl Zeichen: 3467
Kontakt-Informationen:
Ansprechpartner: Dheeraj Shaha
Stadt:
Northbrook
Telefon: 18886006441
Kategorie:
Biotechnologie
Meldungsart: Finanzinformation
Versandart: Veröffentlichung
Freigabedatum: 13.09.2019
Diese Pressemitteilung wurde bisher 443 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Epigenetics | New Technologies Transforming the Industrial Business"
steht unter der journalistisch-redaktionellen Verantwortung von
MnM (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
The growth of this market is mainly driven by factors such as the increasing R&D expenditure in the pharmaceutical industry, increasing focus on miniaturization, technological advancements, and growing prevalence of diseases. The report "Microplate Systems Market by Product (Microplate R
3D Cell Culture Market : Regenerative Medicine to Offer Global Growth In Coming Years ...
A 3D cell culture is an artificially created environment in which biological cells are permitted to grow or interact with their surroundings in all three dimensions. Factors such as rising focus on developing alternative methods for animal testing, funding initiatives from government and private
Immuno Oncology Assays : Research Application Transforming the Industrial Business ...
What the Immuno Oncology Assays Market looks like? Growth in Immuno Oncology Assays Market is largely driven by factors such as the increasing adoption of targeted therapy over traditional therapy and the increasing demand for mAbs. According to the new market research report "Immuno Onco
Weitere Mitteilungen von MnM
CROMSOURCE vertieft sein hybrides Dienstleistungsmodell ...
CROMSOURCE, ein internationales Auftragsforschungsinstitut (contract research organization, CRO) hat die Konsolidierung seines hybriden Dienstleistungsmodells bekanntgegeben. Aufgrund von Kundennachfragen hat CROMSOURCE sein hybrides Dienstleistungsangebot weiter ausgefeilt, so dass das Unterneh
Menarini: Elcin Barker Ergun wird Group CEO ...
Der Vorstand hat Frau Elcin Barker Ergun als CEO der Menarini Group berufen. "Elcin Barker Ergun ist die ideale Verstärkung des Menarini-Teams, um die Wachstumsstrategie bezüglich Märkte und Therapiebereiche voranzutreiben", kommentierte Eric Cornut, Chairman von Menarini. Elc
Strekin AG verkündet den Abschluss der Patientenrekrutierung der RESTORE Phase 3 klinischen Studie mit STR001 ...
Die Strekin AG (www.strekin.com), ein biopharmazeutisches Unternehmen, das sich auf die Behandlung von Hörverlust spezialisiert hat, gab heute bekannt, dass es die Patientenrekrutierung in der RESTORE-Studie erfolgreich abgeschlossen hat. Die RESTORE-Studie ist eine internationale, randomisier
deCODE in Island stimmt Sequenzierung der Hälfte der britischen Biobanken-Teilnehmer zu ...
deCODE genetics in Island hat eine Vereinbarung mit einem Konsortium aus Regierung, Wohltätigkeitsorganisationen, Forschern und weltweit führenden biopharmazeutischen und Healthcare-Unternehmen getroffen, um die komplette Genom-Sequenzierung der britischen Biobank-Teilnehmern durchzuführen. D
